Retatrutide

Retatrutide (LY3437943) is an investigational synthetic peptide from Eli Lilly that activates three metabolic hormone receptors in one molecule: the GLP-1 receptor, the GIP receptor, and the glucagon receptor ¹. It is given as a single weekly under-the-skin (subcutaneous) injection, with a roughly six-day half-life engineered to match once-weekly dosing ²⁰.

The third receptor is what sets it apart. GLP-1-based medicines work mainly by curbing appetite and slowing stomach emptying; adding glucagon signaling also nudges resting energy expenditure upward, while GIP contributes its own insulin-related effects ³. Together these arms have produced trial weight loss beyond earlier single- and dual-agonist comparators ⁴.

Primary research targets are obesity and type 2 diabetes. A 48-week Phase 2 trial reported mean weight loss of 24.2% at 12 mg weekly ¹, and the 40-week Phase 3 TRANSCEND-T2D-1 monotherapy trial cut HbA1c by up to 1.94% ². Secondary areas include metabolic liver disease (MASLD), where liver fat fell more than 80% in a randomized substudy ⁷, plus kidney, sleep apnea, and osteoarthritis programs still underway ¹¹.

Retatrutide is not approved in any country. Supplies outside trials come through an expanded-access pathway reported in 2026 or through unregulated online vendors, where products sold under the name have repeatedly failed composition and labeling checks ¹⁵.

Retatrutide is a triple agonist: one molecule that binds and switches on three related receptors on cell surfaces, all from the same receptor family ¹. Activation raises a messenger molecule called cyclic AMP inside cells, which triggers the downstream effects ².

Each arm contributes something different:

• GLP-1 receptor. Suppresses appetite, slows stomach emptying, and primes glucose-dependent insulin release from the pancreas ².
• GIP receptor. Adds its own insulin-related signaling and participates in energy balance ²¹.
• Glucagon receptor. The differentiator. Glucagon activity increases resting energy expenditure, a pathway single- and dual-agonist GLP-1 drugs do not engage ³.

The glucagon arm explains why weight loss exceeds what eating less alone would predict. Pair-fed and weight-matched animal experiments show an energy-burn component beyond reduced food intake ⁴. In mice engineered without the GLP-1 receptor, retatrutide still normalizes body weight, confirming the effect does not depend on GLP-1 signaling ⁴.

Downstream actions measured in human studies include improved pancreatic beta-cell function and insulin sensitivity ³⁵, suppression of the lipid-regulating protein ANGPTL3/8 ⁹, and a direct effect on heart-muscle contractility seen in isolated human atrial tissue ¹⁸. The simple summary: fewer calories in, more calories out, and better fuel handling, from three receptors working at once.

Weight loss

In the 48-week Phase 2 obesity trial, mean losses were 8.7% at 1 mg, 22.8% at 8 mg, and 24.2% at 12 mg weekly, versus 2.1% on placebo; 63% of the 12 mg group lost at least 20% of starting weight ¹. A systematic review in adults without diabetes found placebo-subtracted loss around 22% ⁴. Company-reported Phase 3 data reach roughly 28.7% mean loss, with about 39% losing at least 30% ¹⁷.

Blood sugar

In type 2 diabetes, 12 mg reduced HbA1c by up to 2.02% in Phase 2 and by 1.94% in the 40-week Phase 3 monotherapy trial, with no severe hypoglycemia ².

Body composition

DEXA substudies report about 23.2% fat-mass reduction, in bariatric-surgery territory; lean mass is largely spared in animal models but still declines in people during rapid weight loss ²¹.

Liver fat

In a 24-week randomized substudy, liver fat fell roughly 81–82% at 8–12 mg, and 86% of the 12 mg group reached normal liver fat, defined as under 5% ⁷.

Lipids, blood pressure, inflammation

Pooled analyses show systolic blood pressure down about 6.8 mmHg, triglycerides down about 41 mg/dL, and LDL-cholesterol down about 13 mg/dL ⁵. Inflammatory markers such as hs-CRP and IL-6 fall substantially in people without diabetes ⁸.

Kidney markers

Post hoc Phase 2 analyses found reduced urine albumin and increased eGFR in the obesity cohort, with a dedicated chronic kidney disease trial underway ¹⁰.

Appetite and behavior

Doses of 4 mg and above reduce appetite, hunger, and the amount of food people anticipate eating; the changes track with weight loss ²³.

All human efficacy data use once-weekly subcutaneous injections at fixed doses that do not scale with body weight ¹. The timeline above reflects the 12 mg arm of the Phase 2 obesity trial, which started at 2 mg and stepped up every 4 weeks.

Studied dose arms, with key outcomes:

• Phase 2 obesity, 48 weeks: 1, 4, 8, 12 mg weekly; −24.2% body weight at 12 mg ¹.
• Phase 3 type 2 diabetes, 40 weeks: 4, 9, 12 mg weekly; HbA1c −1.69 to −1.94% and weight −11.5 to −15.3% ².
• Phase 2 type 2 diabetes, 36 weeks: 0.5, 4, 8, 12 mg weekly; HbA1c up to −2.02% at 12 mg ³.

Dose-response is steep for weight: loss continues without a plateau through 48 weeks, while HbA1c improvements level off around week 24 ¹.

Escalation rate drives tolerability more than total dose. Faster early titration in Phase 2 sent discontinuation into the mid-teens percent; the slower-scheduled Phase 3 trial cut that to 2–5% ². Community protocols mirror the stepwise approach: start at 1–2 mg once weekly, add 1–2 mg every 2–4 weeks toward a 6–12 mg ceiling, and hold at any step until stomach symptoms settle. Most users report stable maintenance at 4–8 mg weekly.

Weight-based rules of thumb (about 0.10–0.15 mg/kg weekly) land typical adults near the same 8–12 mg range; adults under about 60 kg often stay at the lower end for comfort. Cycling is not evidence-based: the molecule clears slowly, with intact drug detectable in plasma roughly 56 days after a 2 mg dose, so restarting after any break means re-titrating from a low starting dose ¹².

Retatrutide is handled as a lyophilized (freeze-dried) powder in research vials, commonly 5, 10, or 12 mg, and mixed into liquid before use. The standard diluent in research practice is bacteriostatic water (0.9% benzyl alcohol), which keeps the solution usable for multiple draws; preservative-free sterile water suits a single use if benzyl alcohol is a concern. Add the diluent slowly against the vial wall, swirl gently rather than shaking, and confirm the solution is clear before measuring. Use the calculator below to work out volumes for a given vial size and dose.

For storage, unmixed vials keep longest frozen (−20°C or colder), with refrigeration (2–8°C) acceptable for months and protection from light and moisture. After mixing, refrigerate and use within about 4–6 weeks; discard anything cloudy, discolored, or containing particles. No published stability data exist for reconstituted retatrutide, so these practices follow standard injectable-peptide handling.

Two cautions. The roughly 56-day plasma detection window reflects slow, depot-like release from under the skin ¹², not the shelf life of a mixed vial. And identity matters outside clinical supply: testing in Australia found composition and labeling failures in products sold as retatrutide ¹⁵, and a counterfeit product has caused serious adverse events ¹⁶. Third-party analytical confirmation (purity and mass identity) is the standard safeguard for research-grade material.

Most interactions flow from two properties: retatrutide lowers blood pressure and lipids on its own, and it slows stomach emptying ⁵.

• Antihypertensives. Expect systolic pressure to fall roughly 7 mmHg in pooled trials ⁵. Doses of blood-pressure medicines often need to come down as treatment proceeds.
• Insulin and sulfonylureas. Retatrutide meaningfully improves insulin sensitivity and beta-cell function ³⁵, and monotherapy caused no severe hypoglycemia ². In type 2 diabetes, adding it to insulin-releasing drugs raises hypoglycemia risk, so trial-style practice reduces those agents at the start.
• Other incretins (semaglutide, tirzepatide, liraglutide). Not stacked; they share the same nausea mechanism, so combinations concentrate gastrointestinal effects. Documented practice is sequential switching with a multi-week washout, restarting the next drug at its introductory dose ².
• Lipid-lowering drugs. Effects add up favorably: retatrutide cuts triglycerides and LDL-cholesterol itself, partly via suppression of the protein ANGPTL3/8 ⁹. Lipids are rechecked within a few months.
• SGLT2 inhibitors. Co-use is trial-established ¹¹; a urinary-tract-infection signal is under investigation ⁵².
• Narrow-index oral drugs. Delayed stomach emptying ³⁷ could shift absorption of warfarin, thyroid hormone, or digoxin during initiation, so those levels are watched.
• Alcohol. In rats, retatrutide weakened alcohol's internal cues ⁵⁴, consistent with less drinking reported by incretin users; heavy drinking stacks dehydration on top of stomach-related fluid losses.
• Antipsychotics. Combining with clozapine, which slows the gut itself, is untested and theoretically additive ³³.

Combination work is mostly early, but a few pairings stand out.

• Cagrilintide (amylin/calcitonin co-agonist). The most data-backed partner: in obese rats, the two together produced dose-dependent weight loss beyond either alone, and the five-receptor strategy is an active development direction ⁵⁵.
• Bimagrumab (activin receptor inhibitor). A theoretical pairing for lean-mass preservation: retatrutide nearly spared lean mass in obese rhesus monkeys ²², and bimagrumab is known to add muscle. No human combination data exist.
• Other incretins. Avoided in combination: same-receptor redundancy adds nausea without clear benefit ². Sequential switching between incretins is the documented alternative.
• Insulin. Only a short overlap in type 2 diabetes, with insulin doses cut at initiation ³⁵. There is no acceptable role with absolute insulin deficiency, where ketoacidosis is documented ¹³.
• Ketogenic regimens and exogenous ketones. Retatrutide raises the body's own fat-oxidation and ketone markers ³⁶; combined ketonemia is an open theoretical question, not an established benefit.

Retatrutide is not approved in the United States, the UK, the European Union, or Australia; it remains in Phase 3 development ². A US expanded-access (compassionate-use) pathway was reported in 2026 ²⁴. Outside trials and that pathway, supply runs through unregulated online vendors, where Australian testing found composition and labeling failures in products sold as retatrutide ¹⁵ and counterfeit-linked serious adverse events are documented ¹⁶.

For sport: no WADA Prohibited List entry is documented in the reviewed literature, but anti-doping laboratories have already validated a detection method to WADA criteria because of concern about misuse among physically active populations ¹². Intact retatrutide is measurable in plasma for roughly 56 days after dosing and does not appear in urine, so blood is the informative sample. If ever prohibited, the substance would fall under category S0, substances without regulatory approval. Community use among online weight-trainer circles for physique purposes is documented ²⁵.

Gastrointestinal events are the headline. Nausea, vomiting, diarrhea, and constipation affected 13–50% of Phase 2 participants, mostly mild to moderate and dose-dependent; slower titration in Phase 3 cut treatment discontinuation to 2–5% ². Network meta-analyses rank retatrutide's adverse-event burden above tirzepatide's, driven almost entirely by gastrointestinal events ⁶. Hypoglycemia is not a feature of monotherapy: no severe episodes occurred in the Phase 3 trial ², though risk rises when combined with insulin or sulfonylureas.

Less common but recognized:

• Resting heart-rate rise. Dose-dependent, and consistent with the direct effect on heart-muscle cells seen in isolated human atrial tissue ¹⁸.

• Dysesthesia. Burning or tingling skin, dose-related in most trials, typically resolving after de-escalation or stopping ²⁸.

• Urinary tract infections. An open pharmacovigilance signal, possibly timing-related, still under investigation ⁵².

• Gallbladder and pancreas events. Recognized class risks of GLP-1-based therapies ⁴⁹.

• Skeletal fragility in older adults. Rapid weight loss can accelerate bone loss; emerging data identify skeletal fragility as a monitoring concern in older adults ⁴⁹.

• Facial volume loss and skin changes. Rapid, large-magnitude weight loss commonly causes significant facial volume loss (“Ozempic face”) and accelerated skin laxity, cosmetic consequences rather than rare events ⁴⁹.

• Severe or intractable diarrhea. Diarrhea is part of the dose-dependent GI profile; when it becomes severe or persistent, hold the dose and discontinue treatment if it does not resolve (practitioner consensus).

Serious in the wrong setting:

• Ketoacidosis with absolute insulin deficiency. Case reports document pH as low as 6.8 and ketones above 6 mmol/L after use by people with type 1 diabetes, worsened by illness and missed insulin ¹³. Retatrutide has no acceptable role in insulin-deficient states.
• Counterfeit product. Serious adverse events are linked to fake product ¹⁶.

Class-level cautions carried over from GLP-1 medicines include medullary thyroid carcinoma or MEN2 history, pancreatitis, gallbladder disease, and pregnancy; pregnancy guidance suggests stopping well before conception because intact drug stays detectable in plasma for about two months ¹². Long-term (multi-year) cancer and eye safety remain open questions pending Phase 3 completion ⁵¹.